Related Experiment Video

Updated: May 24, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies

Ryan P Roop1, Cynthia X Ma

  • 1Washington University School of Medicine in Saint Louis, Department of Medicine, Divisions of Hematology & Oncology, St Louis, MO, USA.

Future Oncology (London, England)
|March 14, 2012
PubMed

Insights

Endocrine resistance in estrogen receptor-positive breast cancer is a major challenge. Understanding cross-talk between ER and growth factor pathways offers new therapeutic targets for treatment.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Endocrine resistance is a significant clinical challenge in estrogen receptor (ER)-positive breast cancer.
  • The underlying mechanisms of endocrine resistance are not fully understood but involve cross-talk between ER and growth factor receptor signaling pathways.
  • This cross-talk contributes to estrogen-independent tumor growth.

Purpose of the Study:

  • To review the current understanding of molecular pathways mediating endocrine resistance in ER-positive breast cancer.
  • To discuss therapeutic targets being evaluated for endocrine-resistant breast cancer.
  • To highlight the need for research strategies addressing molecular heterogeneity.

Main Methods:

  • Literature review of studies investigating endocrine resistance mechanisms.
  • Analysis of molecular pathways involved in ER and growth factor receptor signaling.
  • Evaluation of therapeutic agents targeting these pathways in clinical trials.

Main Results:

  • Cross-talk between ER and growth factor signaling pathways is implicated in endocrine resistance.
  • Various molecular pathways are being explored as therapeutic targets.
  • Agents targeting these pathways have shown promising results in early-phase clinical trials (Phase I/II).

Conclusions:

  • Targeting molecular pathways involved in endocrine resistance is a promising therapeutic strategy for ER-positive breast cancer.
  • Further research and clinical trials are needed to address the molecular heterogeneity of this disease.
  • Development of tailored treatment strategies based on individual tumor characteristics is crucial.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...